Methoxamine hydrochloride
Based on 1 Customer Validation
Methoxamine hydrochloride is a selective alpha1-adrenergic receptor agonist. Methoxamine hydrochloride causes vasoconstriction and increased peripheral vascular resistance. Methoxamine hydrochloride significantly increased the overflow of ATP, ADP and AMP, but not adenosine, by a prazosin-sensitive mechanism in the rabbit pulmonary artery.
For research use only. We do not sell to patients.
- Purity: 99.32%
- CAS No.: 61-16-5
- Formula: C11H18ClNO3
- Molecular Weight:247.72
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Adrenergic Receptor Isoforms
More
Biological Activity
Noradrenergic α1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar-Kyoto rats weighing 320-47 g ( based on the exponentially tapered T-tube model)[2]
-
Dosage:0.025 mg/kg
-
Administration:Femoral vein
-
Result:Had a greater effect on the peripheral resistance vessels than on the Winkessel vessels in the rat systemic circulation.
Chemical Information
-
CAS No. 61-16-5
-
Appearance Solid
-
Molecular Weight 247.72
-
Formula C11H18ClNO3
-
Color White to off-white
-
SMILES
OC(C(N)C)C1=CC(OC)=CC=C1OC.[H]Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 135 mg/mL (544.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (8.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (8.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sanders AB. The roles of methoxamine and norepinephrine in electromechanical dissociation. Ann Emerg Med. 1984;13(9 Pt 2):835-839. [Content Brief]
[2]. Chang KC. Hypertensive effects of methoxamine on arterial mechanics in rats: analysis based on exponentially tapered T-tube model. Eur J Pharmacol. 1998;350(2-3):195-202. [Content Brief]
[3]. Takeuchi K, et al. Methoxamine-induced release of endogenous ATP from rabbit pulmonary artery. Eur J Pharmacol. 1994;254(3):287-290. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0368 mL | 20.1841 mL | 40.3682 mL | 100.9204 mL |
| 5 mM | 0.8074 mL | 4.0368 mL | 8.0736 mL | 20.1841 mL | |
| 10 mM | 0.4037 mL | 2.0184 mL | 4.0368 mL | 10.0920 mL | |
| 15 mM | 0.2691 mL | 1.3456 mL | 2.6912 mL | 6.7280 mL | |
| 20 mM | 0.2018 mL | 1.0092 mL | 2.0184 mL | 5.0460 mL | |
| 25 mM | 0.1615 mL | 0.8074 mL | 1.6147 mL | 4.0368 mL | |
| 30 mM | 0.1346 mL | 0.6728 mL | 1.3456 mL | 3.3640 mL | |
| 40 mM | 0.1009 mL | 0.5046 mL | 1.0092 mL | 2.5230 mL | |
| 50 mM | 0.0807 mL | 0.4037 mL | 0.8074 mL | 2.0184 mL | |
| 60 mM | 0.0673 mL | 0.3364 mL | 0.6728 mL | 1.6820 mL | |
| 80 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.2615 mL | |
| 100 mM | 0.0404 mL | 0.2018 mL | 0.4037 mL | 1.0092 mL |
Methoxamine hydrochloride Related Classifications
HY-B1298 Related Classifications
Powered by Bioz